AU2008250945B2 - Bone targeted alkaline phosphatase, kits and methods of use thereof - Google Patents

Bone targeted alkaline phosphatase, kits and methods of use thereof Download PDF

Info

Publication number
AU2008250945B2
AU2008250945B2 AU2008250945A AU2008250945A AU2008250945B2 AU 2008250945 B2 AU2008250945 B2 AU 2008250945B2 AU 2008250945 A AU2008250945 A AU 2008250945A AU 2008250945 A AU2008250945 A AU 2008250945A AU 2008250945 B2 AU2008250945 B2 AU 2008250945B2
Authority
AU
Australia
Prior art keywords
alkaline phosphatase
amino acid
sequence
residue
signal peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2008250945A
Other languages
English (en)
Other versions
AU2008250945A2 (en
AU2008250945A1 (en
Inventor
Guy Boileau
Philippe Crine
Robert Heft
Hal Landy
Isabelle Lemire
Pierre Leonard
Thomas P. Loisel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2008250945A1 publication Critical patent/AU2008250945A1/en
Publication of AU2008250945A2 publication Critical patent/AU2008250945A2/en
Assigned to ENOBIA CANADA LIMITED PARTNERSHIP reassignment ENOBIA CANADA LIMITED PARTNERSHIP Request for Assignment Assignors: ENOBIA PHARMA INC.
Assigned to ALEXION PHARMA INTERNATIONAL SARL reassignment ALEXION PHARMA INTERNATIONAL SARL Request for Assignment Assignors: ENOBIA CANADA LIMITED PARTNERSHIP
Priority to AU2013203875A priority Critical patent/AU2013203875A1/en
Assigned to ALEXION PHARMA HOLDING reassignment ALEXION PHARMA HOLDING Request for Assignment Assignors: ALEXION PHARMA INTERNATIONAL SARL
Application granted granted Critical
Publication of AU2008250945B2 publication Critical patent/AU2008250945B2/en
Assigned to ALEXION PHARMACEUTICALS, INC. reassignment ALEXION PHARMACEUTICALS, INC. Request for Assignment Assignors: ALEXION PHARMA HOLDING
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2008250945A 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof Active 2031-01-14 AU2008250945B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013203875A AU2013203875A1 (en) 2007-05-11 2013-04-11 Bone Targeted Alkaline Phosphatase, Kits and Methods of Use Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
US60/917,589 2007-05-11
PCT/CA2008/000923 WO2008138131A1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013203875A Division AU2013203875A1 (en) 2007-05-11 2013-04-11 Bone Targeted Alkaline Phosphatase, Kits and Methods of Use Thereof

Publications (3)

Publication Number Publication Date
AU2008250945A1 AU2008250945A1 (en) 2008-11-20
AU2008250945A2 AU2008250945A2 (en) 2009-12-24
AU2008250945B2 true AU2008250945B2 (en) 2013-12-12

Family

ID=40001639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008250945A Active 2031-01-14 AU2008250945B2 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Country Status (25)

Country Link
US (1) US20100297119A1 (enExample)
EP (3) EP2662448B1 (enExample)
JP (1) JP5732603B2 (enExample)
AT (1) ATE536413T1 (enExample)
AU (1) AU2008250945B2 (enExample)
BR (2) BRPI0811198B8 (enExample)
CA (1) CA2687001C (enExample)
CY (1) CY2016005I2 (enExample)
DE (1) DE202008018131U1 (enExample)
DK (3) DK2662448T3 (enExample)
ES (3) ES2471915T3 (enExample)
FR (1) FR16C0007I2 (enExample)
HR (1) HRP20140416T1 (enExample)
HU (2) HUE031655T2 (enExample)
IL (1) IL202057A0 (enExample)
LT (1) LTC2368999I2 (enExample)
LU (1) LU92976I2 (enExample)
ME (1) ME01828B (enExample)
NL (1) NL300798I2 (enExample)
NO (1) NO2016002I1 (enExample)
PL (3) PL2662448T3 (enExample)
PT (3) PT2662448T (enExample)
RS (1) RS53302B (enExample)
SI (2) SI2662448T1 (enExample)
WO (1) WO2008138131A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1759001T3 (pl) * 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
SI2185589T1 (sl) 2007-06-01 2016-04-29 University Of Maryland Baltimore Vezavna sredstva za Fc receptor konstantne regije imunoglobulina
EP2545080B1 (en) 2010-03-12 2017-05-10 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
CN103153344A (zh) * 2010-04-30 2013-06-12 阿莱克森国际制药有限公司 用于治疗基质矿化障碍的方法、组合物、和试剂盒
WO2012016073A2 (en) 2010-07-28 2012-02-02 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
KR20140084201A (ko) * 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
WO2015112017A1 (en) 2014-01-24 2015-07-30 Am-Pharma B.V. Chimeric alkaline phosphatase-like proteins
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
IL309260B2 (en) 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
JP6993961B2 (ja) * 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (en) * 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
EP3368062A4 (en) * 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20180125979A (ko) 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
US20200306350A1 (en) 2016-06-27 2020-10-01 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
IL266977B2 (en) * 2016-11-30 2024-01-01 Purdue Research Foundation Fracture-targeted bone regeneration using thyroid hormone receptor stimulation
BR112019009495A2 (pt) 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
BR112019009484A2 (pt) 2016-12-09 2019-07-30 Gliknik Inc otimização de fabricação de gl-2045, um stradomer multimerizador
EP3592372A4 (en) * 2017-03-09 2021-01-13 Alexion Pharmaceuticals, Inc. GLYCOPROTEIN MANUFACTURING PROCESS
KR20190129058A (ko) * 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
AU2019207600B2 (en) 2018-01-09 2025-01-09 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
EP3768302B1 (en) 2018-03-20 2025-05-07 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
WO2020227263A1 (en) 2019-05-06 2020-11-12 Synthetic Biologics, Inc. Alkaline phosphate-based oncology treatments
EP3975999A4 (en) 2019-06-03 2023-07-19 Theriva Biologics, Inc. ALKALINE PHOSPHATASE FORMULATIONS AND THEIR USES
CA3161266A1 (en) * 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2021138581A1 (en) 2020-01-03 2021-07-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tnap locally administered for promoting periodontal health
EP4162036A1 (en) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
JP2023540098A (ja) * 2020-09-03 2023-09-21 チェン アーヴィン エス．ワイ． 可溶性アルカリホスファターゼ構築物及び可溶性アルカリホスファターゼ構築物をコードするポリヌクレオチドを含む発現ベクター
US12611447B2 (en) 2020-09-04 2026-04-28 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
AU2022218782B2 (en) 2021-02-12 2026-06-25 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CA3263089A1 (en) * 2022-08-31 2024-03-07 University Of Utah Research Foundation GJA1-20K COMPOSITIONS AND METHODS FOR MITIGATING ISCHEMIC-REPERFUSION INJURY

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103263A1 (en) * 2004-04-21 2005-11-03 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
WO2001036620A2 (en) 1999-11-16 2001-05-25 Genzyme Corporation Vectors and transgenies with regulatory elements for gene delivery to the liver
WO2002092134A1 (en) 2001-05-14 2002-11-21 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
US20070081984A1 (en) * 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
BRPI0512496A (pt) 2004-06-23 2008-03-04 Genzyme Corp processos e composições para o tratamento de doenças policìsticas
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
BRPI0515819A (pt) 2004-12-01 2008-08-05 Genzyme Corp métodos para o fornecimento direcionado de material genético ao fìgado

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103263A1 (en) * 2004-04-21 2005-11-03 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone

Also Published As

Publication number Publication date
CA2687001C (en) 2019-02-12
PL2368999T3 (pl) 2014-08-29
PT2158319E (pt) 2012-03-06
EP2158319A4 (en) 2010-07-21
BR122019000505A2 (pt) 2021-12-14
NL300798I1 (enExample) 2016-03-16
PL2158319T4 (pl) 2016-04-29
HK1141047A1 (en) 2010-10-29
BRPI0811198B1 (pt) 2021-03-09
EP2662448B1 (en) 2016-12-21
HUS1600005I1 (hu) 2016-02-29
WO2008138131A1 (en) 2008-11-20
SI2662448T1 (sl) 2017-05-31
ME01828B (me) 2014-12-20
US20100297119A1 (en) 2010-11-25
NO2016002I2 (no) 2016-02-02
FR16C0007I2 (fr) 2017-01-27
PL2158319T3 (pl) 2012-05-31
AU2008250945A2 (en) 2009-12-24
CY2016005I1 (el) 2016-08-31
ES2471915T3 (es) 2014-06-27
CA2687001A1 (en) 2008-11-20
CY2016005I2 (el) 2016-08-31
WO2008138131A4 (en) 2008-12-31
NO2016002I1 (no) 2016-02-02
AU2008250945A1 (en) 2008-11-20
DK2662448T3 (en) 2017-03-20
BRPI0811198A8 (pt) 2018-08-14
WO2008138131A9 (en) 2009-08-06
EP2158319A1 (en) 2010-03-03
DK2158319T3 (da) 2012-03-19
DE202008018131U1 (de) 2011-12-30
JP5732603B2 (ja) 2015-06-10
HK1162589A1 (en) 2012-08-31
BRPI0811198A2 (pt) 2014-10-21
NL300798I2 (enExample) 2016-03-16
ATE536413T1 (de) 2011-12-15
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
PT2662448T (pt) 2017-03-29
PT2368999E (pt) 2014-05-26
PL2662448T3 (pl) 2017-07-31
HRP20140416T1 (hr) 2014-06-20
HK1191372A1 (en) 2014-07-25
RS53302B (sr) 2014-08-29
BR122019000505B1 (pt) 2022-01-18
ES2619332T3 (es) 2017-06-26
DK2368999T3 (da) 2014-05-26
LTC2368999I2 (lt) 2017-09-25
BRPI0811198B8 (pt) 2021-05-25
IL202057A0 (en) 2011-08-01
EP2158319B1 (en) 2011-12-07
FR16C0007I1 (enExample) 2016-04-15
JP2010526543A (ja) 2010-08-05
ES2380546T3 (es) 2012-05-16
SI2368999T1 (sl) 2014-07-31
LTPA2016004I1 (lt) 2016-02-25
EP2368999B1 (en) 2014-03-12
LU92976I2 (en) 2016-04-11
EP2368999A1 (en) 2011-09-28

Similar Documents

Publication Publication Date Title
EP2662448B1 (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
US11224638B2 (en) Treating seizure with recombinant alkaline phosphatase
US9988620B2 (en) Methods, compositions, and kits for the treatment of matrix mineralization disorders
AU2008216896A1 (en) Activin-actriia antagonists and uses for promoting bone growth in cancer patients
HK1191372B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
HK1162589B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
HK1141047B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
AU2013203875A1 (en) Bone Targeted Alkaline Phosphatase, Kits and Methods of Use Thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 NOV 2009

PC1 Assignment before grant (sect. 113)

Owner name: ENOBIA CANADA LIMITED PARTNERSHIP

Free format text: FORMER APPLICANT(S): ENOBIA PHARMA INC.

PC1 Assignment before grant (sect. 113)

Owner name: ALEXION PHARMA INTERNATIONAL SARL

Free format text: FORMER APPLICANT(S): ENOBIA CANADA LIMITED PARTNERSHIP

PC1 Assignment before grant (sect. 113)

Owner name: ALEXION PHARMA HOLDING

Free format text: FORMER APPLICANT(S): ALEXION PHARMA INTERNATIONAL SARL

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALEXION PHARMACEUTICALS, INC.

Free format text: FORMER OWNER WAS: ALEXION PHARMA HOLDING

NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: STRENSIQ ASFOTASE ALFA RCH

Filing date: 20160114

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: STRENSIQ ASFOTASE ALFA RCH

Filing date: 20160114

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: STRENSIQ ASFOTASE ALFA RCH

Filing date: 20160114

Extension date: 20310114